Caffyns 7%pf (78GL) News

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering

ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 8-K - Current report

ENDRA Provides Update Following In-person Meeting with FDA

Increases clarity for ENDRA on regulatory path forward for TAEUS ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update

Conference call begins at 4:30 p.m. Eastern time today ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound...

Form 8-K - Current report

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]